Pedro Bergo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pedro Bergo has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Maria Helena Rigatto
Universidade Federal do Rio Grande do Sul
2 shared publications Alessandra Mascarello
Departamento de Química, Universidade Federal de Santa Catarina (UFSC), Florianópolis, Brazil
1 shared publicationAlexandre P. Zavascki
Infectious Diseases Service, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil; Department of Internal Medicine, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
1 shared publication- Anderson Rodrigo Moraes de Oliveira
Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, 14040-901, Ribeirao Preto, SP, Brazil
1 shared publication Andressa Barros
Medical Sciences Postgraduate Program, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Infection Control Service, Hospital São Lucas da PUCRS, Porto Alegre, RS, Brazil
1 shared publicationAnne D. Villela
Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF) and Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 March 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 28, 130-135
Antimicrobial stewardship programme associated with earlier prescription of in vitro susceptible therapy and lower 14-day mortality in patients with carbapenem-resistant Enterobacterales bacteraemia: a cohort study
- 1 March 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 28, 130-135
Open AccessAntimicrobial stewardship programme associated with earlier prescription of in vitro susceptible therapy and lower 14-day mortality in patients with carbapenem-resistant Enterobacterales bacteraemia: a cohort study
- Open Access
- 16 August 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (8) , e0202568
Pre-clinical evaluation of quinoxaline-derived chalcones in tuberculosis
New effective compounds for tuberculosis treatment are needed. This study evaluated the effects of a series of quinoxaline-derived chalcones against laboratorial strains and clinical isolates of M. tuberculosis. Six molecules, namely N5, N9, N10, N15, N16, and N23 inhibited the growth of the M. tuberculosis H37Rv laboratorial strain. The three compounds (N9, N15 and N23) with the lowest MIC values were further tested against clinical isolates and laboratory strains with mutations in katG or inhA genes. From these data, N9 was selected as the lead compound for further investigation. Importantly, this chalcone displayed a synergistic effect when combined with moxifloxacin. Noteworthy, the anti-tubercular effects of N9 did not rely on inhibition of mycolic acids synthesis, circumventing important mechanisms of resistance. Interactions with cytochrome P450 isoforms and toxic effects were assessed in silico and in vitro. The chalcone N9 was not predicted to elicit any mutagenic, genotoxic, irritant, or reproductive effects, according to in silico analysis. Additionally, N9 did not cause mutagenicity or genotoxicity, as revealed by Salmonella/microsome and alkaline comet assays, respectively. Moreover, N9 did not inhibit the cytochrome P450 isoforms CYP3A4/5, CYP2C9, and CYP2C19. N9 can be considered a potential lead molecule for development of a new anti-tubercular therapeutic agent.
- 16 August 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (8) , e0202568
Open AccessPre-clinical evaluation of quinoxaline-derived chalcones in tuberculosis
New effective compounds for tuberculosis treatment are needed. This study evaluated the effects of a series of quinoxaline-derived chalcones against laboratorial strains and clinical isolates of M. tuberculosis. Six molecules, namely N5, N9, N10, N15, N16, and N23 inhibited the growth of the M. tuberculosis H37Rv laboratorial strain. The three compounds (N9, N15 and N23) with the lowest MIC values were further tested against clinical isolates and laboratory strains with mutations in katG or inhA genes. From these data, N9 was selected as the lead compound for further investigation. Importantly, this chalcone displayed a synergistic effect when combined with moxifloxacin. Noteworthy, the anti-tubercular effects of N9 did not rely on inhibition of mycolic acids synthesis, circumventing important mechanisms of resistance. Interactions with cytochrome P450 isoforms and toxic effects were assessed in silico and in vitro. The chalcone N9 was not predicted to elicit any mutagenic, genotoxic, irritant, or reproductive effects, according to in silico analysis. Additionally, N9 did not cause mutagenicity or genotoxicity, as revealed by Salmonella/microsome and alkaline comet assays, respectively. Moreover, N9 did not inhibit the cytochrome P450 isoforms CYP3A4/5, CYP2C9, and CYP2C19. N9 can be considered a potential lead molecule for development of a new anti-tubercular therapeutic agent.
- 1 March 2018
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 52 (1) , 86-89
Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery
- 1 March 2018
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 52 (1) , 86-89
Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery